Articles from Pluristyx, Inc.

The up to $1.4M collaboration will enable manufacturing “universal” islets containing a drug-inducible safety feature designed to make curative therapies accessible without the need for chronic immunosuppression

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading biotechnology company specializing in tools and technologies for the development of induced pluripotent stem cell (iPSC)-based therapies, today announced the execution of two significant commercial clinical use licensing agreements. These agreements provide two innovative therapeutics companies with access to Pluristyx's clinical-grade iPSC lines and proprietary gene engineering platform technologies to develop next-generation, living-medicine, cell therapies.

SEATTLE and TELFORD, Pa., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc. and Solesis, LLC today announced the signing of a Memorandum of Understanding (MOU) establishing their strategic collaboration. The primary objective is to optimize a combination of technologies to provide researchers with standardized, reliable, reproducible tools, addressing a critical need in the application of pluripotent stem cells for research, diagnostics, and therapeutics.

Pluristyx, Inc. and Stem Genomics SAS today announce the closing of an equity investment and strategic partnership in Stem Genomics. Through the partnership, the companies will offer a unified pathway to allow customers to evaluate the genomic stability of Pluristyx’s pluripotent stem cell (PSC) lines using Stem Genomics’ iCS-digital™ PSC assay.

Pluristyx, Inc. today announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs). This collaboration will make it possible to accelerate the scalable, consistent, and cost-effective manufacturing of stem cell derived products for patient administration.

Pluristyx, Inc., an advanced therapy tools and services biotechnology company, and Accelerated Biosciences, a regenerative medicine innovator in the use of proprietary human trophoblast stem cells (hTSCs), today announced they signed an agreement for Pluristyx to manufacture clinical grade hTSC banks under Good Manufacturing Practices (GMP). Accelerated Biosciences will use and make these stem cell banks available to commercial partners for further manufacturing of advanced biologic and cellular therapies. hTSCs have unique legal, ethical, and intellectual property advantages, including a high expansion capacity and a unique genetic identity not associated with any person or embryo, making them the ideal starting material for manufacturing the next generation of advanced therapies.

Pluristyx, Inc., an advanced therapy tools and services biotechnology company, panCELLa, a privately held biotechnology company, and Implant Therapeutics, a developer of genetically engineered stem cells, today announced they have entered into a manufacturing and distribution strategic alliance that offers cell therapy companies streamlined access to the next generation of safe, universal, cost-effective, “off-the-shelf” induced pluripotent stem cells (iPSCs). The agreement will enable commercial access to iPSCs containing panCELLa’s FailSafe™ and Implant’s hypoimmunogenic technology derived from fully consented and regulatory appropriate donors. Both research and clinical grade panCELLa-owned iPSC lines will be manufactured and distributed by Pluristyx, who will also make custom iPSC lines incorporating panCELLa and Implant technology to meet unique customer needs.